GHK vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Extremely short as free peptide; tissue binding extends local effects
- ~7 days
- Admin Route
- SubQ, Topical, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 100–500 mcg
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Daily or 5x per week
- Once weekly
- Key Benefits
- Stimulates collagen and extracellular matrix synthesis
- Activates tissue repair gene expression programs
- Anti-aging: reverses 57% of age-related gene changes
- Antioxidant and anti-inflammatory
- Wound healing and skin barrier repair
- Improves skin laxity, texture, and radiance
- Neuroprotective (stimulates NGF, BDNF)
- Anti-fibrotic in liver and lung models
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Excellent safety profile (naturally occurring peptide)
- Rare: mild injection site reaction (SC)
- No significant adverse effects identified in research
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —